Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 May;41(5):1593-1603.
doi: 10.1007/s10792-021-01691-7. Epub 2021 Feb 9.

Ahmed glaucoma valve implantation with and without subconjunctival bevacizumab in refractory glaucoma

Reza Zarei  1 , Mehrbod Ghasempour  1 , Ghasem Fakhraie  1 , Yahya Eslami  1 , Massood Mohammadi  1 , Nikoo Hamzeh  1 , Fereydun Sajadi  1 , Mona Safizadeh  2
Affiliations
Randomized Controlled Trial

Ahmed glaucoma valve implantation with and without subconjunctival bevacizumab in refractory glaucoma

Reza Zarei et al. Int Ophthalmol. 2021 May.

Abstract

Purpose: To evaluate the effects of subconjunctival bevacizumab injection on intraocular pressure (IOP), hypertensive phase, and failure and success rates of Ahmed Glaucoma Valve (AGV) implantation.

Methods: A total of 63 eyes of 63 patients (30 cases in control and 33 cases in bevacizumab group) were included in this randomized masked prospective clinical trial. Pre- and postoperative BCVA, IOP, number of medications, complications and success rates were compared between AGV + bevacizumab and AGV alone group.

Results: Both groups showed statistically significant reductions in IOP in all their follow-up visits (P < 0.05). The mean IOP was lower in the AGV + Bevacizumab group than AGV group in all follow-up visits. However, the difference was only significant at the 3rd month (17.3 ± 6.2 vs. 20.7 ± 4.6, p = 0.04). The number of medications was not differed significantly between the two groups at their last visit (p value = 0.84) Complete success rate was higher in AGV + Bevacizumab. However, the difference was not significant (p = 0.73). The qualified and overall success rate, failure rate and the need for second tube were not statistically different between the two groups. The hypertensive phase was not statistically significant between the 2 groups (33.3% in AGV + Bevacizumab group and 50% in AGV group, p = 0.06) CONCLUSION: Adjunctive use of Bevacizumab during AGV implantation is beneficial in controlling hypertensive phase and IOP control and may lead to higher success rates and lower failure rates after AGV implantation. However, whether it's clearly beneficial or its exact role remains to be investigated.

Keywords: Anti-fibrotic agents; Bevacizumab; Neovascular glaucoma; Open angle glaucoma.

PubMed Disclaimer

References

    1. Tailor R, Kinsella MT, Clarke JC (2018) Long-term outcome of intravitreal bevacizumab followed by ahmed valve implantation in the management of neovascular glaucoma. Semin ophthalmol 33:606–612 - DOI
    1. Assaad MH, Baerveldt G, Rockwood EJ (1999) Glaucoma drainage devices: pros and cons. Curr Opin Ophthalmol 10:147–153 - DOI
    1. Coleman AL, Hill R, Wilson MR et al (1995) Initial clinical experience with the Ahmed Glaucoma valve implant. Am J Ophthalmol 120:23–31 - DOI
    1. Eid TE, Katz LJ, Spaeth GL et al (1997) Tube-shunt surgery versus neodymium:YAG cyclophotocoagulation in the management of neovascular glaucoma. Ophthalmology 104:1692–1700 - DOI
    1. Katz LJ, Spaeth GL (1987) Surgical management of the secondary glaucomas: part I. Ophthalmic Surg 18:826–834 - PubMed

Publication types

LinkOut - more resources